Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjneurology logo
VJDementia
Logo
  • Home (current)
  • Diseases
    Alzheimer's Disease
    Dementia
    Dementia with Lewy Bodies
    Frontotemporal Dementia
    Vascular Dementia
    Mild Cognitive Impairment
    View all Diseases
  • Topics
    Diagnostics
    Biology
    Communication
    Treatment
    Care Practice
    Prevention
    View all Topics
  • Conferences
    CTAD 2022
    AAIC 2022
    EAN 2022
    ESOC 2022
    AAN 2022
    CONy 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Treatment

Lecanemab: drawbacks to consider 3:02
Lecanemab: drawbacks to consider
Alvaro Pascual-Leone • 9 Jan 2023
Lecanemab: a review 5:24
Lecanemab: a review
Alvaro Pascual-Leone • 9 Jan 2023
FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis? 2:10
FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?
Alvaro Pascual-Leone • 9 Jan 2023
Lecanemab vs aducanumab 1:35
Lecanemab vs aducanumab
Alvaro Pascual-Leone • 9 Jan 2023
Targeting the pancreas to treat Alzheimer’s disease 5:44
Targeting the pancreas to treat Alzheimer’s disease
Florin Despa • 28 Nov 2022
Diabetes-associated cognitive dysfunction 3:01
Diabetes-associated cognitive dysfunction
Florin Despa • 28 Nov 2022
New pivotal study using photobiomodulation in Alzheimer’s treatment 7:29
New pivotal study using photobiomodulation in Alzheimer’s treatment
Jacques Touchon • 9 Dec 2022
The regulatory role of nicotinic receptors in cognitive functioning 2:36
The regulatory role of nicotinic receptors in cognitive functioning
Paul Newhouse • 23 Nov 2022
The importance of using systems biology based approaches in AD research 7:25
The importance of using systems biology based approaches in AD research
Jared Roach • 22 Nov 2022
How effective are cholinergic agents beyond MCI? 1:36
How effective are cholinergic agents beyond MCI?
Paul Newhouse • 23 Nov 2022
Highlights from CTAD 2022 3:55
Highlights from CTAD 2022
Jacques Touchon • 9 Dec 2022
Prioritizing the mechanistic understanding of AD to improve treatments 1:50
Prioritizing the mechanistic understanding of AD to improve treatments
Jared Roach • 22 Nov 2022
Photobiomodulation: why target the brain and the gut? 2:53
Photobiomodulation: why target the brain and the gut?
Jacques Touchon • 9 Dec 2022
APOE-targeted epigenome therapy for Alzheimer’s disease 3:12
APOE-targeted epigenome therapy for Alzheimer’s disease
Ornit Chiba-Falek • 6 Dec 2022
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk 5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain • 6 Dec 2022
First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD 13:27
First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD
Jesse Cedarbaum • 1 Dec 2022
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJDementia via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJDementia logo
The content of VJDementia is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy